GO:0003979 UDP-glucose 6-dehydrogenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003979 (UDP-glucose 6-dehydrogenase activity) catalyzes the NAD+-dependent oxidation of UDP-alpha-D-glucose to UDP-alpha-D-glucuronate, a key step in glycosaminoglycan and glucuronidation pathways.
• The enzyme UGDH is the primary protein responsible for this activity and is implicated in cancer progression, metastasis, drug resistance, and developmental epileptic encephalopathy.
• UGDH modulates hyaluronic acid production and promotes breast cancer progression.
• Loss-of-function mutations in UGDH cause recessive developmental epileptic encephalopathy.
• UGDH regulates the unfolded protein response and affects sorafenib sensitivity in hepatocellular carcinoma.
• UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis.
Description
UDP-glucose 6-dehydrogenase activity (GO:0003979) is a molecular function that catalyzes the conversion of UDP-alpha-D-glucose to UDP-alpha-D-glucuronate, a critical precursor for glycosaminoglycan synthesis and glucuronidation reactions. This activity is essential for maintaining cellular UDP-glucuronate pools, which are required for the biosynthesis of hyaluronic acid, chondroitin sulfate, and other extracellular matrix components. Researchers study this term because dysregulation of UDP-glucose 6-dehydrogenase activity has been linked to cancer progression, metastasis, drug resistance, and neurological disorders. The enzyme responsible for this activity, UGDH, is a promising therapeutic target in oncology and metabolic diseases.
UDP-glucose 6-dehydrogenase activity At A Glance
| GO ID | GO:0003979 |
|---|---|
| GO term | UDP-glucose 6-dehydrogenase activity |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Catalysis of the reaction: H2O + 2 NAD+ + UDP-alpha-D-glucose = 3 H+ + 2 NADH + UDP-alpha-D-glucuronate. |
| Major function | Oxidation of UDP-glucose to UDP-glucuronate, a precursor for glycosaminoglycans and glucuronidation. |
| Cofactor | NAD+ |
| Substrate | UDP-alpha-D-glucose |
| Product | UDP-alpha-D-glucuronate |
What Is GO:0003979?
According to the Gene Ontology, GO:0003979 (UDP-glucose 6-dehydrogenase activity) is defined as the catalysis of the reaction: H2O + 2 NAD+ + UDP-alpha-D-glucose = 3 H+ + 2 NADH + UDP-alpha-D-glucuronate. In other words, it is the NAD+-dependent oxidation of UDP-glucose to UDP-glucuronate, a key step in glucuronidation and glycosaminoglycan biosynthesis.
Why Is UDP-glucose 6-dehydrogenase activity Important in Cell Biology?
UDP-glucose 6-dehydrogenase activity is critical for the biosynthesis of UDP-glucuronate, which serves as a substrate for glycosaminoglycan production and phase II glucuronidation. This activity influences cell surface properties, extracellular matrix remodeling, and immune regulation. Dysregulation of this activity is associated with cancer progression, metastasis, and drug resistance, making it a target for therapeutic intervention. Additionally, loss-of-function mutations in the enzyme cause developmental epileptic encephalopathy, highlighting its importance in neurodevelopment.
• Provides UDP-glucuronate for hyaluronic acid synthesis, promoting cancer progression.
• Regulates unfolded protein response and sorafenib sensitivity in hepatocellular carcinoma.
• Modulates lung cancer metastasis via SNAI1 mRNA decay.
• Plays a role in gut-liver immune regulation through glucuronidation.
• Alters the CNS tumor immune microenvironment in glioblastoma.
• Inhibits glioblastoma growth and migration when targeted.
• Loss-of-function mutations cause recessive developmental epileptic encephalopathy.
• Controls RIPK1-driven liver damage in nonalcoholic steatohepatitis.
What Happens During UDP-glucose 6-dehydrogenase activity?
Substrate Binding and Oxidation
In simple terms: The enzyme grabs UDP-glucose and removes electrons from it.
UDP-glucose 6-dehydrogenase binds UDP-alpha-D-glucose and catalyzes its oxidation using NAD+ as an electron acceptor, forming UDP-alpha-D-glucuronate and NADH.
NAD+ Cofactor Utilization
In simple terms: NAD+ acts as a helper molecule that accepts electrons.
The reaction requires two NAD+ molecules per UDP-glucose, which are reduced to NADH, driving the oxidative decarboxylation at the C6 position.
Product Formation and Pathway Integration
In simple terms: The product UDP-glucuronate is used to build complex sugars and modify other molecules.
UDP-alpha-D-glucuronate is a precursor for glycosaminoglycans such as hyaluronic acid and chondroitin sulfate, and is also used in glucuronidation reactions that regulate immune and metabolic processes.
Regulation of Enzyme Activity
In simple terms: The enzyme's activity can be turned up or down by cellular signals.
UGDH activity is regulated by its expression levels and post-translational modifications, and its dysregulation is linked to cancer and neurological disorders.
Key Genes Involved in GO:0003979 UDP-glucose 6-dehydrogenase activity
The following genes and proteins are directly involved in or regulate UDP-glucose 6-dehydrogenase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UGDH | Encodes UDP-glucose 6-dehydrogenase, the enzyme catalyzing GO:0003979 | Target in cancer, epilepsy, and liver disease |
| NAD+ | Cofactor for the dehydrogenase reaction | Essential for enzymatic activity |
| UDP-glucose | Substrate for the reaction | Precursor for UDP-glucuronate |
| UDP-glucuronate | Product of the reaction | Used in glycosaminoglycan synthesis and glucuronidation |
| Hyaluronic acid | Downstream product of UDP-glucuronate | Promotes cancer progression |
| SNAI1 | mRNA stability regulated by UDP-glucose | Affects lung cancer metastasis |
| RIPK1 | Regulated by UDP-glucuronate metabolism | Drives liver damage in NASH |
| HSPA5 | Unfolded protein response marker | Modulated by UGDH in sorafenib sensitivity |
| CD44 | Hyaluronic acid receptor | Linked to breast cancer progression |
| HAS2 | Hyaluronic acid synthase | Uses UDP-glucuronate for HA synthesis |
| CHSY1 | Chondroitin sulfate synthase | Uses UDP-glucuronate |
| UGT enzymes | Glucuronosyltransferases | Use UDP-glucuronate for glucuronidation |
| NADH | Reduced cofactor produced | Reflects dehydrogenase activity |
| SLC2A1 | Glucose transporter | Affects UDP-glucose levels |
| GFPT1 | Hexosamine pathway enzyme | Influences UDP-GlcNAc and UDP-glucose pools |
| PGM1 | Phosphoglucomutase | Produces glucose-1-phosphate for UDP-glucose synthesis |
| UGP2 | UDP-glucose pyrophosphorylase | Synthesizes UDP-glucose |
| GALE | UDP-galactose 4-epimerase | Interconverts UDP-glucose and UDP-galactose |
How Is UDP-glucose 6-dehydrogenase activity Regulated?
UGDH activity is regulated at multiple levels. Its expression is influenced by oncogenic signaling pathways, and its activity can be modulated by substrate availability and NAD+ levels. In glioblastoma, targeting UGDH alters the immune microenvironment, suggesting regulation by tumor microenvironment factors. Loss-of-function mutations in UGDH cause developmental epileptic encephalopathy, indicating tight regulation is critical for normal neurodevelopment. Additionally, UDP-glucuronate metabolism controls RIPK1-driven liver damage, linking UGDH activity to inflammatory signaling.
UDP-glucose 6-dehydrogenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| UGDH | Breast cancer progression | UGDH knockout or overexpression in breast cancer cell lines |
| UGDH | Glioblastoma growth and migration | UGDH knockout in glioblastoma cell lines and xenografts |
| UGDH | Developmental epileptic encephalopathy | Patient-derived iPSCs or UGDH mutant mouse models |
| UGDH | Nonalcoholic steatohepatitis | Liver-specific UGDH knockout mice |
| UGDH | Sorafenib resistance in hepatocellular carcinoma | UGDH overexpression in HCC cell lines |
Cancer Progression and Metastasis
UGDH-mediated UDP-glucose 6-dehydrogenase activity promotes breast cancer progression by regulating hyaluronic acid production. In lung cancer, UDP-glucose accelerates SNAI1 mRNA decay and impairs metastasis. Targeting UGDH inhibits glioblastoma growth and migration and alters the CNS tumor immune microenvironment. UGDH also lessens sorafenib sensitivity in hepatocellular carcinoma via modulating the unfolded protein response.
Developmental Epileptic Encephalopathy
Loss-of-function mutations in UDP-glucose 6-dehydrogenase cause recessive developmental epileptic encephalopathy, highlighting the essential role of this activity in brain development.
Liver Disease and Immune Regulation
UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis. UGDH-mediated glucuronidation also plays an emerging role in gut-liver immune regulation.
From UDP-glucose 6-dehydrogenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does UGDH loss affect cancer cell proliferation? | UGDH knockout cell lines (CRISPR-Cas9) |
| Does a specific UGDH mutation cause epilepsy? | Point-mutation knock-in mice or patient iPSCs |
| Can UGDH overexpression drive metastasis? | UGDH overexpression cell lines and xenografts |
| How does UGDH affect hyaluronic acid production? | Tagged knock-in of UGDH with HA-binding protein imaging |
| What is the role of UGDH in liver immune regulation? | Liver-specific UGDH knockout mice |
| Does UGDH modulate sorafenib sensitivity? | UGDH knockout or overexpression in HCC cells |
How to Study the UDP-glucose 6-dehydrogenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADH absorbance assay | Enzyme activity | Kinetic studies of UGDH |
| LC-MS/MS | UDP-glucose and UDP-glucuronate levels | Metabolic flux analysis |
| CRISPR knockout screen | Gene essentiality | Identifying UGDH dependencies |
| RNA-seq | Transcriptome changes | Unfolded protein response profiling |
| Proteomics | Protein expression and modifications | Pathway analysis |
| Immunohistochemistry | UGDH expression in tissues | Cancer prognosis |
| Hyaluronic acid binding assay | HA production | Extracellular matrix studies |
| RIPK1 kinase assay | RIPK1 activation | Liver damage models |
Enzymatic Activity Assays
UDP-glucose 6-dehydrogenase activity can be measured spectrophotometrically by monitoring NADH production at 340 nm using purified enzyme or cell lysates.
Metabolite Profiling
LC-MS/MS can quantify UDP-glucose and UDP-glucuronate levels to assess flux through the pathway.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that modulate UGDH dependency in cancer cells.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal changes in glycosaminoglycan synthesis and unfolded protein response upon UGDH perturbation.
How CRISPR Can Be Used to Study GO:0003979 UDP-glucose 6-dehydrogenase activity
Knockout
CRISPR-Cas9 knockout of UGDH eliminates UDP-glucose 6-dehydrogenase activity, enabling studies of its role in cancer proliferation, metastasis, and drug sensitivity.
Point Mutation
Introducing patient-specific UGDH mutations via CRISPR base editing or HDR can model developmental epileptic encephalopathy and dissect structure-function relationships.
Knock-in
Tagged knock-in of UGDH (e.g., GFP or HA tag) allows live-cell imaging and proteomic analysis of the enzyme's localization and interactions.
Overexpression
CRISPR activation or lentiviral overexpression of UGDH can model increased UDP-glucuronate production and its effects on hyaluronic acid synthesis and tumor progression.
How EDITGENE Supports UDP-glucose 6-dehydrogenase activity Research
Researchers studying UDP-glucose 6-dehydrogenase activity-related genes often need to determine whether a candidate gene is causally involved in disease phenotypes, metabolic flux, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for UDP-glucose 6-dehydrogenase activity research.
Frequently Asked Questions About UDP-glucose 6-dehydrogenase activity
What is UDP-glucose 6-dehydrogenase activity?
It is the enzymatic activity (GO:0003979) that catalyzes the NAD+-dependent oxidation of UDP-glucose to UDP-glucuronate, a key step in glycosaminoglycan synthesis and glucuronidation.
What genes are involved in UDP-glucose 6-dehydrogenase activity?
The primary gene is UGDH, which encodes the enzyme. Other genes such as UGP2, GALE, and HAS2 influence substrate availability and downstream product utilization.
What diseases are associated with UDP-glucose 6-dehydrogenase activity?
Dysregulation is linked to breast cancer, glioblastoma, lung cancer metastasis, hepatocellular carcinoma, developmental epileptic encephalopathy, and nonalcoholic steatohepatitis.
How is UDP-glucose 6-dehydrogenase activity measured?
It can be measured by NADH production at 340 nm or by LC-MS/MS quantification of UDP-glucuronate.
What is the role of UGDH in cancer?
UGDH promotes cancer progression by supplying UDP-glucuronate for hyaluronic acid synthesis, modulating the unfolded protein response, and affecting drug sensitivity.
Can CRISPR be used to study UDP-glucose 6-dehydrogenase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise functional studies of UGDH and its pathway.
What is the reaction catalyzed by UDP-glucose 6-dehydrogenase?
H2O + 2 NAD+ + UDP-alpha-D-glucose = 3 H+ + 2 NADH + UDP-alpha-D-glucuronate.
Is UDP-glucose 6-dehydrogenase activity involved in epilepsy?
Yes, loss-of-function mutations in UGDH cause recessive developmental epileptic encephalopathy.
How does UDP-glucuronate metabolism affect liver disease?
UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis, highlighting its role in liver immune regulation.
What model systems are used to study UDP-glucose 6-dehydrogenase activity?
Common models include CRISPR knockout cell lines, patient-derived iPSCs, and liver-specific or brain-specific knockout mice.
Conclusion
UDP-glucose 6-dehydrogenase activity (GO:0003979) is a fundamental molecular function that bridges glucose metabolism, glycosaminoglycan biosynthesis, and glucuronidation. Its dysregulation contributes to cancer progression, metastasis, drug resistance, epilepsy, and liver disease. Understanding this activity through CRISPR-based models and multi-omics approaches offers promising avenues for therapeutic development. EDITGENE provides the tools and expertise to accelerate research on this critical enzyme.
References
- 1. Guo B et al.. 2022. UDP-glucose 6-dehydrogenase lessens sorafenib sensitivity via modulating unfolded protein response.. Biochem Biophys Res Commun 613:207-213 PMID: 35617808
- 2. Arnold JM et al.. 2020. UDP-glucose 6-dehydrogenase regulates hyaluronic acid production and promotes breast cancer progression.. Oncogene 39(15):3089-3101 PMID: 31308490
- 3. Wang X et al.. 2019. UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis.. Nature 571(7763):127-131 PMID: 31243371
- 4. Yang YQ et al.. 2025. Uridine diphosphate-glucose 6-dehydrogenase-mediated glucuronidation and its emerging role in gut-liver immune regulation.. World J Gastrointest Oncol 17(10):110464 PMID: 41114112
- 5. Zhan D et al.. 2022. Targeting UDP-α-d-glucose 6-dehydrogenase alters the CNS tumor immune microenvironment and inhibits glioblastoma growth.. Genes Dis 9(3):717-730 PMID: 35782977
- 6. Oyinlade O et al.. 2018. Targeting UDP-α-D-glucose 6-dehydrogenase inhibits glioblastoma growth and migration.. Oncogene 37(20):2615-2629 PMID: 29479058
- 7. Hengel H et al.. 2020. Loss-of-function mutations in UDP-Glucose 6-Dehydrogenase cause recessive developmental epileptic encephalopathy.. Nat Commun 11(1):595 PMID: 32001716
- 8. Zhang T et al.. 2023. UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis.. Nat Commun 14(1):2715 PMID: 37169760
